NOS3 and Huntington disease: It Is worth emphasising that in our study, there was no difference in plasma P levels between the groups with type 2 DM and those without DM or between the groups with D and without D. It seems that the accumulation of certain uraemic toxins that function as eNOS inhibitors, such as asymmetric dimethylarginine and advanced glycation end products (AGEs), were produced in similar concentrations in all of our HD patients, irrespective of the coexistence of diabetes mellitus or dyslipidaemia.